APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pigmented Villonodular Synovitis Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pigmented Villonodular Synovitis Drug Market Outlook and Growth Opportunities 2026

19 December 2025198 pages

Choose your research edition.

Industry ResearchPigmented Villonodular Synovitis Drug Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal Pigmented Villonodular Synovitis Drug Industry Growth and Trends Forecast to 203276 pages · $3,450 USDMarket StructureGlobal Pigmented Villonodular Synovitis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032171 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pigmented Villonodular Synovitis Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Pigmented Villonodular Synovitis Drug Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Pigmented Villonodular Synovitis Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pigmented Villonodular Synovitis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pigmented Villonodular Synovitis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pigmented Villonodular Synovitis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pigmented Villonodular Synovitis Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pigmented Villonodular Synovitis Drug market include Novartis AG, Bristol-Myers Squibb Co, Plexxikon Inc and F. Hoffmann-La Roche Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pigmented Villonodular Synovitis Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pigmented Villonodular Synovitis Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pigmented Villonodular Synovitis Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pigmented Villonodular Synovitis Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Pigmented Villonodular Synovitis Drug Segment by Company

Novartis AG

Bristol-Myers Squibb Co

Plexxikon Inc

F. Hoffmann-La Roche Ltd

Pigmented Villonodular Synovitis Drug Segment by Type

Nilotinib

Cabiralizumab

Emactuzumab

Mcs-110

Others

Pigmented Villonodular Synovitis Drug Segment by Application

Hospital

Clinic

Others

Pigmented Villonodular Synovitis Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Pigmented Villonodular Synovitis Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Pigmented Villonodular Synovitis Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pigmented Villonodular Synovitis Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Pigmented Villonodular Synovitis Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pigmented Villonodular Synovitis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pigmented Villonodular Synovitis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pigmented Villonodular Synovitis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pigmented Villonodular Synovitis Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pigmented Villonodular Synovitis Drug industry.

Chapter 3: Detailed analysis of Pigmented Villonodular Synovitis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Pigmented Villonodular Synovitis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Pigmented Villonodular Synovitis Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pigmented Villonodular Synovitis Drug Industry Trends Table 2. Pigmented Villonodular Synovitis Drug Industry Drivers Table 3. Pigmented Villonodular Synovitis Drug Industry Opportunities and Challenges Table 4. Pigmented Villonodular Synovitis Drug Industry Restraints Table 5. Global Pigmented Villonodular Synovitis Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pigmented Villonodular Synovitis Drug Revenue Share by Company (2021-2026) Table 7. Global Pigmented Villonodular Synovitis Drug Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Pigmented Villonodular Synovitis Drug Sales Volume Share by Company (2021-2026) Table 9. Global Pigmented Villonodular Synovitis Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Pigmented Villonodular Synovitis Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Pigmented Villonodular Synovitis Drug Key Company Manufacturing Base & Headquarters Table 12. Global Pigmented Villonodular Synovitis Drug Company, Product Type & Application Table 13. Global Pigmented Villonodular Synovitis Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Pigmented Villonodular Synovitis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Nilotinib Table 18. Significant Companies of Cabiralizumab Table 19. Significant Companies of Emactuzumab Table 20. Significant Companies of Mcs-110 Table 21. Significant Companies of Others Table 22. Global Pigmented Villonodular Synovitis Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Pigmented Villonodular Synovitis Drug Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Pigmented Villonodular Synovitis Drug Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Pigmented Villonodular Synovitis Drug Sales Volume Share by Type (2021-2026) Table 26. Global Pigmented Villonodular Synovitis Drug Sales Volume Share by Type (2027-2032) Table 27. Global Pigmented Villonodular Synovitis Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Pigmented Villonodular Synovitis Drug Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Pigmented Villonodular Synovitis Drug Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Pigmented Villonodular Synovitis Drug Sales Value Share by Type (2021-2026) Table 31. Global Pigmented Villonodular Synovitis Drug Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Hospital Table 33. Significant Companies of Clinic Table 34. Significant Companies of Others Table 35. Global Pigmented Villonodular Synovitis Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Pigmented Villonodular Synovitis Drug Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Pigmented Villonodular Synovitis Drug Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Pigmented Villonodular Synovitis Drug Sales Volume Share by Application (2021-2026) Table 39. Global Pigmented Villonodular Synovitis Drug Sales Volume Share by Application (2027-2032) Table 40. Global Pigmented Villonodular Synovitis Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Pigmented Villonodular Synovitis Drug Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Pigmented Villonodular Synovitis Drug Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Pigmented Villonodular Synovitis Drug Sales Value Share by Application (2021-2026) Table 44. Global Pigmented Villonodular Synovitis Drug Sales Value Share by Application (2027-2032) Table 45. Global Pigmented Villonodular Synovitis Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Pigmented Villonodular Synovitis Drug Sales by Region (2021-2026) & (K Units) Table 47. Global Pigmented Villonodular Synovitis Drug Sales Market Share by Region (2021-2026) Table 48. Global Pigmented Villonodular Synovitis Drug Sales by Region (2027-2032) & (K Units) Table 49. Global Pigmented Villonodular Synovitis Drug Sales Market Share by Region (2027-2032) Table 50. Global Pigmented Villonodular Synovitis Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Pigmented Villonodular Synovitis Drug Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Pigmented Villonodular Synovitis Drug Sales Value Share by Region (2021-2026) Table 53. Global Pigmented Villonodular Synovitis Drug Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Pigmented Villonodular Synovitis Drug Sales Value Share by Region (2027-2032) Table 55. Global Pigmented Villonodular Synovitis Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Pigmented Villonodular Synovitis Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Pigmented Villonodular Synovitis Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Pigmented Villonodular Synovitis Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Pigmented Villonodular Synovitis Drug Sales by Country (2021-2026) & (K Units) Table 60. Global Pigmented Villonodular Synovitis Drug Sales Market Share by Country (2021-2026) Table 61. Global Pigmented Villonodular Synovitis Drug Sales by Country (2027-2032) & (K Units) Table 62. Global Pigmented Villonodular Synovitis Drug Sales Market Share by Country (2027-2032) Table 63. Global Pigmented Villonodular Synovitis Drug Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Pigmented Villonodular Synovitis Drug Sales Value Market Share by Country (2021-2026) Table 65. Global Pigmented Villonodular Synovitis Drug Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Pigmented Villonodular Synovitis Drug Sales Value Market Share by Country (2027-2032) Table 67. Novartis AG Company Information Table 68. Novartis AG Business Overview Table 69. Novartis AG Pigmented Villonodular Synovitis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Novartis AG Pigmented Villonodular Synovitis Drug Product Portfolio Table 71. Novartis AG Recent Development Table 72. Bristol-Myers Squibb Co Company Information Table 73. Bristol-Myers Squibb Co Business Overview Table 74. Bristol-Myers Squibb Co Pigmented Villonodular Synovitis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Bristol-Myers Squibb Co Pigmented Villonodular Synovitis Drug Product Portfolio Table 76. Bristol-Myers Squibb Co Recent Development Table 77. Plexxikon Inc Company Information Table 78. Plexxikon Inc Business Overview Table 79. Plexxikon Inc Pigmented Villonodular Synovitis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Plexxikon Inc Pigmented Villonodular Synovitis Drug Product Portfolio Table 81. Plexxikon Inc Recent Development Table 82. F. Hoffmann-La Roche Ltd Company Information Table 83. F. Hoffmann-La Roche Ltd Business Overview Table 84. F. Hoffmann-La Roche Ltd Pigmented Villonodular Synovitis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. F. Hoffmann-La Roche Ltd Pigmented Villonodular Synovitis Drug Product Portfolio Table 86. F. Hoffmann-La Roche Ltd Recent Development Table 87. Key Raw Materials Table 88. Raw Materials Key Suppliers Table 89. Pigmented Villonodular Synovitis Drug Distributors List Table 90. Pigmented Villonodular Synovitis Drug Customers List Table 91. Research Programs/Design for This Report Table 92. Authors List of This Report Table 93. Secondary Sources Table 94. Primary Sources List of Figures Figure 1. Pigmented Villonodular Synovitis Drug Product Image Figure 2. Global Pigmented Villonodular Synovitis Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pigmented Villonodular Synovitis Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Pigmented Villonodular Synovitis Drug Sales (2021-2032) & (K Units) Figure 5. Global Pigmented Villonodular Synovitis Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Pigmented Villonodular Synovitis Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Nilotinib Image Figure 10. Cabiralizumab Image Figure 11. Emactuzumab Image Figure 12. Mcs-110 Image Figure 13. Others Image Figure 14. Global Pigmented Villonodular Synovitis Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Pigmented Villonodular Synovitis Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Pigmented Villonodular Synovitis Drug Sales Volume Share by Type (2021-2032) Figure 17. Global Pigmented Villonodular Synovitis Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Pigmented Villonodular Synovitis Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Pigmented Villonodular Synovitis Drug Sales Value Share by Type (2021-2032) Figure 20. Hospital Image Figure 21. Clinic Image Figure 22. Others Image Figure 23. Global Pigmented Villonodular Synovitis Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Pigmented Villonodular Synovitis Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Pigmented Villonodular Synovitis Drug Sales Volume Share by Application (2021-2032) Figure 26. Global Pigmented Villonodular Synovitis Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Pigmented Villonodular Synovitis Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Pigmented Villonodular Synovitis Drug Sales Value Share by Application (2021-2032) Figure 29. Global Pigmented Villonodular Synovitis Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Pigmented Villonodular Synovitis Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Pigmented Villonodular Synovitis Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Pigmented Villonodular Synovitis Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Pigmented Villonodular Synovitis Drug Sales Value (2021-2032) & (US$ Million) Figure 34. North America Pigmented Villonodular Synovitis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Pigmented Villonodular Synovitis Drug Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Pigmented Villonodular Synovitis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Pigmented Villonodular Synovitis Drug Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Pigmented Villonodular Synovitis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Pigmented Villonodular Synovitis Drug Sales Value (2021-2032) & (US$ Million) Figure 40. South America Pigmented Villonodular Synovitis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Pigmented Villonodular Synovitis Drug Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Pigmented Villonodular Synovitis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Pigmented Villonodular Synovitis Drug Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Pigmented Villonodular Synovitis Drug Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Nilotinib
  • Cabiralizumab
  • Emactuzumab
  • Mcs-110
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Novartis AG
  • Bristol-Myers Squibb Co
  • Plexxikon Inc
  • F. Hoffmann-La Roche Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Pigmented Villonodular Synovitis Drug Sales Value (2021-2032)
  4. 1.2.2 Global Pigmented Villonodular Synovitis Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Pigmented Villonodular Synovitis Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Pigmented Villonodular Synovitis Drug Market Dynamics
  1. 2.1 Pigmented Villonodular Synovitis Drug Industry Trends
  2. 2.2 Pigmented Villonodular Synovitis Drug Industry Drivers
  3. 2.3 Pigmented Villonodular Synovitis Drug Industry Opportunities and Challenges
  4. 2.4 Pigmented Villonodular Synovitis Drug Industry Restraints
3 Pigmented Villonodular Synovitis Drug Market by Company
  1. 3.1 Global Pigmented Villonodular Synovitis Drug Company Revenue Ranking in 2025
  2. 3.2 Global Pigmented Villonodular Synovitis Drug Revenue by Company (2021-2026)
  3. 3.3 Global Pigmented Villonodular Synovitis Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Pigmented Villonodular Synovitis Drug Average Price by Company (2021-2026)
  5. 3.5 Global Pigmented Villonodular Synovitis Drug Company Ranking (2024-2026)
  6. 3.6 Global Pigmented Villonodular Synovitis Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Pigmented Villonodular Synovitis Drug Company Product Type and Application
  8. 3.8 Global Pigmented Villonodular Synovitis Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Pigmented Villonodular Synovitis Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Pigmented Villonodular Synovitis Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Pigmented Villonodular Synovitis Drug Market by Type
  1. 4.1 Pigmented Villonodular Synovitis Drug Type Introduction
  2. 4.1.1 Nilotinib
  3. 4.1.2 Cabiralizumab
  4. 4.1.3 Emactuzumab
  5. 4.1.4 Mcs-110
  6. 4.1.5 Others
  7. 4.2 Global Pigmented Villonodular Synovitis Drug Sales Volume by Type
  8. 4.2.1 Global Pigmented Villonodular Synovitis Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Pigmented Villonodular Synovitis Drug Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Pigmented Villonodular Synovitis Drug Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Pigmented Villonodular Synovitis Drug Sales Value by Type
  12. 4.3.1 Global Pigmented Villonodular Synovitis Drug Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Pigmented Villonodular Synovitis Drug Sales Value by Type (2021-2032)
  14. 4.3.3 Global Pigmented Villonodular Synovitis Drug Sales Value Share by Type (2021-2032)
5 Pigmented Villonodular Synovitis Drug Market by Application
  1. 5.1 Pigmented Villonodular Synovitis Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Pigmented Villonodular Synovitis Drug Sales Volume by Application
  6. 5.2.1 Global Pigmented Villonodular Synovitis Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Pigmented Villonodular Synovitis Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Pigmented Villonodular Synovitis Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Pigmented Villonodular Synovitis Drug Sales Value by Application
  10. 5.3.1 Global Pigmented Villonodular Synovitis Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Pigmented Villonodular Synovitis Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Pigmented Villonodular Synovitis Drug Sales Value Share by Application (2021-2032)
6 Pigmented Villonodular Synovitis Drug Regional Sales and Value Analysis
  1. 6.1 Global Pigmented Villonodular Synovitis Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pigmented Villonodular Synovitis Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Pigmented Villonodular Synovitis Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Pigmented Villonodular Synovitis Drug Sales by Region (2027-2032)
  5. 6.3 Global Pigmented Villonodular Synovitis Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Pigmented Villonodular Synovitis Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Pigmented Villonodular Synovitis Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Pigmented Villonodular Synovitis Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Pigmented Villonodular Synovitis Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Pigmented Villonodular Synovitis Drug Sales Value (2021-2032)
  12. 6.6.2 North America Pigmented Villonodular Synovitis Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Pigmented Villonodular Synovitis Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Pigmented Villonodular Synovitis Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Pigmented Villonodular Synovitis Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Pigmented Villonodular Synovitis Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Pigmented Villonodular Synovitis Drug Sales Value (2021-2032)
  21. 6.9.2 South America Pigmented Villonodular Synovitis Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Pigmented Villonodular Synovitis Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Pigmented Villonodular Synovitis Drug Sales Value Share by Country, 2025 VS 2032
7 Pigmented Villonodular Synovitis Drug Country-level Sales and Value Analysis
  1. 7.1 Global Pigmented Villonodular Synovitis Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pigmented Villonodular Synovitis Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Pigmented Villonodular Synovitis Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Pigmented Villonodular Synovitis Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Pigmented Villonodular Synovitis Drug Sales by Country (2027-2032)
  6. 7.4 Global Pigmented Villonodular Synovitis Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Pigmented Villonodular Synovitis Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Pigmented Villonodular Synovitis Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Pigmented Villonodular Synovitis Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Pigmented Villonodular Synovitis Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Pigmented Villonodular Synovitis Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG Pigmented Villonodular Synovitis Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG Pigmented Villonodular Synovitis Drug Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 Bristol-Myers Squibb Co
  8. 8.2.1 Bristol-Myers Squibb Co Company Information
  9. 8.2.2 Bristol-Myers Squibb Co Business Overview
  10. 8.2.3 Bristol-Myers Squibb Co Pigmented Villonodular Synovitis Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Bristol-Myers Squibb Co Pigmented Villonodular Synovitis Drug Product Portfolio
  12. 8.2.5 Bristol-Myers Squibb Co Recent Developments
  13. 8.3 Plexxikon Inc
  14. 8.3.1 Plexxikon Inc Company Information
  15. 8.3.2 Plexxikon Inc Business Overview
  16. 8.3.3 Plexxikon Inc Pigmented Villonodular Synovitis Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Plexxikon Inc Pigmented Villonodular Synovitis Drug Product Portfolio
  18. 8.3.5 Plexxikon Inc Recent Developments
  19. 8.4 F. Hoffmann-La Roche Ltd
  20. 8.4.1 F. Hoffmann-La Roche Ltd Company Information
  21. 8.4.2 F. Hoffmann-La Roche Ltd Business Overview
  22. 8.4.3 F. Hoffmann-La Roche Ltd Pigmented Villonodular Synovitis Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 F. Hoffmann-La Roche Ltd Pigmented Villonodular Synovitis Drug Product Portfolio
  24. 8.4.5 F. Hoffmann-La Roche Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pigmented Villonodular Synovitis Drug Value Chain Analysis
  2. 9.1.1 Pigmented Villonodular Synovitis Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pigmented Villonodular Synovitis Drug Sales Mode & Process
  6. 9.2 Pigmented Villonodular Synovitis Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pigmented Villonodular Synovitis Drug Distributors
  9. 9.2.3 Pigmented Villonodular Synovitis Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst